Ensysce Biosciences amends Series C preferred terms, removes cash redemption right

Ensysce Biosciences amended on Sept. 25, 2026 its Series C non-voting convertible preferred certificate to eliminate a holder cash-redemption right tied to failed share delivery; the amendment took effect upon filing.